Edgar Filing: Akebia Therapeutics, Inc. - Form 4

Akebia Therapeu	utics, Inc.									
Form 4 March 10, 2015										
FORM 4	L UNITED	STATES	SECU	RITIES A	AND EX	CHANG	E COMMISSIO		PPROVAL	
				ashington				Number:	3235-0287	
Check this bo if no longer					DENIER			Expires:	January 31, 2005	
subject to Section 16. Form 4 or	SIAIEN	VIENT O	F CHAI	NGES IN SECUI	WNERSHIP OF	Estimated burden hou response	average Jrs per			
Form 5 obligations may continue. <i>See</i> Instruction 1(b).	Section 17((a) of the	Public U		ding Cor	npany Ac	ange Act of 1934, t of 1935 or Secti 1940			
(Print or Type Respo	onses)									
1. Name and Addre Butler John P.	2. Issuer Name and Ticker or Trading Symbol Akebia Therapeutics, Inc. [AKBA]			5. Relationship of Reporting Person(s) to Issuer						
(Last)	(First) (Middle)		of Earliest T		. [(Check all applicable)			
C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE			(Month/Day/Year) 03/06/2015			X Director 10% Owner X Officer (give title Other (specify below) below) CEO and President				
1100	(Street)		4 10 4			,			(0) 1	
CAMPDIDGE	Filed(Month/Day/Year)			Applicable Line) _X_ Form filed by	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
CAMBRIDGE,	MA 02142						Person		1 0	
(City)	(State)	(Zip)	Tał	ole I - Non-l	Derivative	Securities .	Acquired, Disposed	of, or Beneficia	lly Owned	
	ransaction Date nth/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D) Price	(Instr. 3 and 4)			
Reminder: Report o	n a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
					inforn requii	nation con red to resp iys a curre	spond to the colle Itained in this forn bond unless the fo ently valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab			curities Acq ls, warrants			r Beneficially Owner securities)	đ		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: Akebia Therapeutics, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securitie Acquired Disposed (Instr. 3, 5)	(A) or of (D)	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	7 (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 11.15	03/06/2015		А	150,00	0	<u>(1)</u>	03/06/2025	Common Stock	150,000

Reporting Owners

Reporting Owner Name / Address	Relationships							
F	Director	10% Owner	Officer	Other				
Butler John P. C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET, SUITE 1100 CAMBRIDGE, MA 02142	Х		CEO and Presid	dent				
Signatures								
Nicole R. Hadas, attorney-in-fact for Jol Butler	nn P.	P. 03/10/2015						
**Signature of Reporting Person		D	ate					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.